Survodutide
Same-day shipping — Ships next business day, cutoff 3 PM ET.
≥99% purity verified by independent HPLC and mass spectrometry (MS) through Janoshik Analytical. Intended for laboratory research use only; not for human consumption, diagnosis, or treatment. View transparency report Compliance PDFs
Documentation & standards
- How to Read a Peptide Certificate of Analysis (COA)
- Peptide Storage and Handling: Temperature, Light and Stability
- Research-Use-Only Compliance: What the Label Obligates
Dual GLP-1/glucagon receptor agonist studied in metabolic and energy regulation research.
Mix and match any items — discount applies automatically at checkout.
Reminder email when it's time to reorder. No card on file. Cancel anytime from your account — or email support@aresresearchlab.com.
Batch transparency
- Batch / lot
- Released with your order
- Testing lab
- Janoshik Analytical
- Purity (HPLC)
- ≥99% target spec
- Identity (MS)
- Available on request
- Report issued
- Available on request
- Full PDF report
- By request
Every request returns a reference number and a live status page. See all published batch records →
For laboratory research use only — not for human or veterinary use.
Earn 64 loyalty points on this purchase · 100 pts = $5 off
Create a Research Account to unlock full batch data, COAs, and priority releases.
Intended strictly for research and laboratory use only. Not for human consumption.
About Survodutide
Third-party purity testing available upon request.
Research Classification
Storage Information
Survodutide Purity & COA Verification
For laboratory research use only. Not for human consumption, diagnosis, or treatment.
Read the Survodutide research
Research guide on Survodutide (BI 456906): dual GLP-1 / glucagon receptor agonism, MASLD and metabolic literature, and the documented side-effect profile.
Read article →Published benefits, side effects, and semaglutide/Retatrutide comparisons for tirzepatide — the GLP-1/GIP dual agonist that established GIP-receptor co-agonism as a productive metabolic axis.
Read article →Published benefits, side effects, and tirzepatide/semaglutide comparisons for Retatrutide — the investigational GLP-1/GIP/glucagon triple agonist with the largest body-weight reductions reported for any non-surgical incretin pharmacotherapy.
Read article →Reference dose tiers, titration ladder, reconstitution math, and weekly-injection scheduling from the published survodutide (GLP-1/glucagon dual agonist) research record.
Read article →How Ares compares for Survodutide
Independent, documentation-first breakdowns of the vendors researchers most often ask about for this compound. COA verification, US shipping, and sourcing transparency, side by side.
Frequently bought together
Curated complements for this compound — researchers most often pair it with these.
Research Use Disclaimer
Researcher Reviews
Sign in with the account that placed your order to leave a verified review.
Ask the Lab
No public questions yet — be the first to ask.
All testing documentation and COA data are provided for laboratory research use only and are not intended to support human consumption, diagnostic, or therapeutic use.
Independent Certificate of Analysis
Independently tested by In-House Verification. Verified and batch-tracked by Ares Research. Additional reports available upon request.
No fillers. No shortcuts. Only verified compounds.
